AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 71 min read$SOPH

Puylaert Kevin sold $2K of SOPH

Puylaert Kevin (Chief Sales Officer) sold 216 shares of SOPHiA GENETICS SA (SOPH) at an average of $8.04 ($7.92–$8.06) across 2 trades on 2026-10-05.

Original reporting
SEC EDGAR · Puylaert Kevin
Published Oct 7, 2026, 8:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 8:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SOPH
Neutral
high confidence
Mentioned
$SOPH
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SOPHNeutralLow
01

Why it matters

The disclosed sale is minor and unlikely to move the stock price materially.

02

Market read

A routine insider sell with negligible trading relevance.

03

What to watch

Potential upcoming corporate actions or personal liquidity needs not disclosed.

Relevance 3/10Novelty 3/10Timing: after-market filing today

Background

Form 4 filings disclose insider transactions; small sales are routine and often have limited market impact.

Company-level read

Ticker impact

$SOPHNeutralHigh confidence
Context

Chief Sales Officer Kevin Puylaert sold 216 shares for $1,736.62 via a Form 4 filing on 2026-10-05.

Expected impact

likely slight downward pressure as market prices in the small sale

Evidence & confidence

The transaction size is minimal relative to total holdings and market cap, limiting material impact.

Market effects

Sector

none

Regional

none

Global

none

Counterpoint

What could challenge this read

The sale could be interpreted as insider confidence if viewed as portfolio rebalancing rather than lack of faith.

Key entities

  • company
    SOPHiA GENETICS SA

    Swiss biotech firm listed on NASDAQ under SOPH.

  • person
    Kevin Puylaert

    Chief Sales Officer of SOPHiA GENETICS SA.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SOPH insider trading history →

Related articles

AUG 11
$SOPHMedAI 8/10

SOPHiA GENETICS (SOPH) Q2 2026 Earnings Call Transcript

SOPHiA GENETICS SA (SOPH) reported Q2 2026 revenue of $23.3 million, up 27%, and an adjusted EBITDA loss of $8.8 million. Platform analysis volume rose 22% to 115,000 patient analyses. Management raised full-year revenue guidance to $94 million to $96 million and reaffirmed adjusted EBITDA loss of $29 million to $32 million, citing U.S. in-house testing demand and biopharma growth.

fool.com6 min
AUG 4
$SOPHHighAI 9/10

SOPHiA GENETICS Reports Second Quarter 2026 Results

SOPHiA GENETICS (Nasdaq: SOPH) reported Q2 2026 revenue of $23.3 million, up 27% year over year, with gross margin of 64.6% reported and 72.1% adjusted. Net loss was $22.4 million and adjusted EBITDA loss was $8.8 million, improving 27%. The company raised 2026 revenue guidance to $94-$96 million and signed AstraZeneca companion diagnostic programs.

prnewswire.com6 min
AUG 4
$SOPHMed

SOPHiA GENETICS SA (SOPH): Financial results for Q2 2026

SOPHiA GENETICS SA (SOPH) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 SOPHiA GENETICS Reports Second Quarter 2026 Results BOSTON, United States and ROLLE, Switzerland, August 4, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the second quarter ended June 30,

SEC EDGAR 6-K2 min
AUG 4
$SOPHMed

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies

SOPHiA GENETICS (NASDAQ: SOPH) said it entered a multi-year collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics for precision oncology therapies. SOPHiA will advance its Solid Tumor decentralized CDx and develop a Hematological Oncology application for blood cancer. The programs aim to support commercialization of AstraZeneca therapies.

finanznachrichten.de4 min